Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cole S. Gilsdorf"'
Autor:
Tamara S. Rodems, Erika Heninger, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Kristin N. Carlson, Madison R. Kircher, Anupama Singh, Timothy E. G. Krueger, David J. Beebe, David F. Jarrard, Douglas G. McNeel, Michael C. Haffner, Joshua M. Lang
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-16 (2022)
Loss of HLA-I gene expression in prostate cancer is associated with repressive chromatin states, which can be reversed by pharmacological DNMT and HDAC inhibition leading to increased activation of co-cultured tumor-specific CD8+ T-cells.
Externí odkaz:
https://doaj.org/article/1153e9cc0b6a481e85909d4a3f28af7d
Autor:
Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.Methods We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex
Externí odkaz:
https://doaj.org/article/ec5e2f5145314e94b0c25808c0d5eee0
Autor:
Tamara S. Rodems, Duane S. Juang, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Tim E. G. Krueger, Erika Heninger, Shuang G. Zhao, Jamie M. Sperger, David J. Beebe, Michael C. Haffner, Joshua M. Lang
Publikováno v:
Clinical Epigenetics. 14
Background DNA methylation alterations have emerged as hallmarks of cancer and have been proposed as screening, prognostic, and predictive biomarkers. Traditional approaches for methylation analysis have relied on bisulfite conversion of DNA, which c
Autor:
Tamara S. Rodems, Erika Heninger, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Kristin N. Carlson, Madison R. Kircher, Anupama Singh, Timothy E. G. Krueger, David J. Beebe, David F. Jarrard, Douglas G. McNeel, Michael C. Haffner, Joshua M. Lang
Publikováno v:
Communications biology. 5(1)
Downregulation of HLA class I (HLA-I) impairs immune recognition and surveillance in prostate cancer and may underlie the ineffectiveness of checkpoint blockade. However, the molecular mechanisms regulating HLA-I loss in prostate cancer have not been
Autor:
Marina N. Sharifi, Kyle T. Helzer, Jamie M. Sperger, Matthew L. Bootsma, Hannah Krause, Cole S. Gilsdorf, Serena K. Wolfe, Zachary Kauffman, Amye J. Tevaarwerk, Mark E. Burkard, Amanda M. Parkes, Ruth M. O'Regan, Kari B. Wisinski, Shuang G. Zhao, Joshua M. Lang
Publikováno v:
Cancer Research. 82:1955-1955
Background: Phosphatidylinositol-3-kinase (PI3K) activating mutations are found in 30-40% of breast cancers, and the PI3K inhibitor alpelisib is FDA-approved for PIK3CA-mutated hormone-receptor positive metastatic breast cancer (MBC). However, rates